137 related articles for article (PubMed ID: 38901675)
21. Modification of Three Amino Acids in Sodium Taurocholate Cotransporting Polypeptide Renders Mice Susceptible to Infection with Hepatitis D Virus In Vivo.
He W; Cao Z; Mao F; Ren B; Li Y; Li D; Li H; Peng B; Yan H; Qi Y; Sun Y; Wang F; Sui J; Li W
J Virol; 2016 Oct; 90(19):8866-74. PubMed ID: 27466423
[TBL] [Abstract][Full Text] [Related]
22. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
[TBL] [Abstract][Full Text] [Related]
23. The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D.
Abbas Z; Saad M; Asim M; Abbas M; Samejo SA
Turk J Gastroenterol; 2020 Feb; 31(2):136-141. PubMed ID: 32141822
[TBL] [Abstract][Full Text] [Related]
24. Role of Sodium Taurocholate Cotransporting Polypeptide as a New Reporter and Drug-Screening Platform: Implications for Preventing Hepatitis B Virus Infections.
Wu MR; Huang YY; Hsiao JK
Mol Imaging Biol; 2020 Apr; 22(2):313-323. PubMed ID: 31140111
[TBL] [Abstract][Full Text] [Related]
25. Bulevirtide for HBV and HDV infections.
Yardeni D; Koh C
Drugs Today (Barc); 2021 Jul; 57(7):433-448. PubMed ID: 34268531
[TBL] [Abstract][Full Text] [Related]
26. Future treatments for hepatitis delta virus infection.
Asselah T; Loureiro D; Tout I; Castelnau C; Boyer N; Marcellin P; Mansouri A
Liver Int; 2020 Feb; 40 Suppl 1():54-60. PubMed ID: 32077603
[TBL] [Abstract][Full Text] [Related]
27. Interactions of Na
Zakrzewicz D; Geyer J
Biol Chem; 2023 Jun; 404(7):673-690. PubMed ID: 37103224
[TBL] [Abstract][Full Text] [Related]
28. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies.
Lampertico P; Roulot D; Wedemeyer H
J Hepatol; 2022 Nov; 77(5):1422-1430. PubMed ID: 35752223
[TBL] [Abstract][Full Text] [Related]
29. Bulevirtide-based treatment strategies for chronic hepatitis delta: A review.
Degasperi E; Anolli MP; Lampertico P
J Viral Hepat; 2023 Apr; 30 Suppl 1():26-32. PubMed ID: 36740364
[TBL] [Abstract][Full Text] [Related]
30. Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.
Sandmann L; Deterding K; Bremer B; Port K; Cornberg M; Wedemeyer H; Maasoumy B
J Viral Hepat; 2023 Apr; 30(4):283-286. PubMed ID: 36648369
[TBL] [Abstract][Full Text] [Related]
31. Effects of polymorphisms in interferon λ 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection.
Yilmaz E; Baran B; Soyer OM; Onel M; Onel D; Ormeci AC; Gokturk S; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S; Karaca C
Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1753-8. PubMed ID: 24582569
[TBL] [Abstract][Full Text] [Related]
32. Hepatic Expression of the Na
Tremmel R; Nies AT; van Eijck BAC; Handin N; Haag M; Winter S; Büttner FA; Kölz C; Klein F; Mazzola P; Hofmann U; Klein K; Hoffmann P; Nöthen MM; Gaugaz FZ; Artursson P; Schwab M; Schaeffeler E
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806468
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
[TBL] [Abstract][Full Text] [Related]
34. Bulevirtide and emerging drugs for the treatment of hepatitis D.
Xu HY; Yang JO; Chen PH; Han SB
Expert Opin Biol Ther; 2023; 23(12):1245-1253. PubMed ID: 37853604
[TBL] [Abstract][Full Text] [Related]
35. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide.
Yan H; Peng B; He W; Zhong G; Qi Y; Ren B; Gao Z; Jing Z; Song M; Xu G; Sui J; Li W
J Virol; 2013 Jul; 87(14):7977-91. PubMed ID: 23678176
[TBL] [Abstract][Full Text] [Related]
36. Effect of mTOR inhibitors on sodium taurocholate cotransporting polypeptide (NTCP) function
Saran C; Ho H; Honkakoski P; Brouwer KLR
Front Pharmacol; 2023; 14():1147495. PubMed ID: 37033614
[TBL] [Abstract][Full Text] [Related]
37. NTCP polymorphisms were associated with fibrosis development in patients with chronic HBV infection.
Su Z; Cai B; Wu X; Li L; Wei B; Meng L; Wang L; Wang L
J Infect Dev Ctries; 2022 Jan; 16(1):179-186. PubMed ID: 35192536
[TBL] [Abstract][Full Text] [Related]
38. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Wedemeyer H; Aleman S; Brunetto MR; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Manuilov D; Suri V; An Q; Da B; Flaherty J; Osinusi A; Liu Y; Merle U; Schulze Zur Wiesch J; Zeuzem S; Ciesek S; Cornberg M; Lampertico P;
N Engl J Med; 2023 Jul; 389(1):22-32. PubMed ID: 37345876
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection.
Herta T; Hahn M; Maier M; Fischer J; Niemeyer J; Hönemann M; Böhlig A; Gerhardt F; Schindler A; Schumacher J; Berg T; Wiegand J; van Bömmel F
Pathogens; 2022 Apr; 11(5):. PubMed ID: 35631038
[TBL] [Abstract][Full Text] [Related]
40. The p.Ser267Phe variant of sodium taurocholate cotransporting polypeptide (NTCP) supports HBV infection with a low efficiency.
Liu C; Xu G; Gao Z; Zhou Z; Guo G; Li D; Jing Z; Sui J; Li W
Virology; 2018 Sep; 522():168-176. PubMed ID: 30032030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
